source
- RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 successRevMed and BeOne have entered a partnership granting BeOne rights to commercialize RevMed’s RAS pathway drugs in selected Asian markets. The agreement also includes collaboration on upcoming clini…
- BioNTech veteran secures $25M seed round for virtual cancer surveillance startupA new virtual cancer surveillance company has closed a $25 million seed round, with the funding led by investors attracted to its novel approach to monitoring tumors. The company is headed by Ryan…